BPC-157 and TB-500 became two of the most popular research-chemical peptides in recent years, marketed heavily for injury recovery and tissue repair. Their path through FDA review illustrates exactly how the compounding eligibility process works, and why popularity alone doesn't determine a substance's regulatory fate.
The 503A Bulk Substances Process
Substances used in compounding that aren't components of an already-approved drug have to go through a nomination and review process for the FDA's 503A bulk drug substances list. The agency, advised by the Pharmacy Compounding Advisory Committee, evaluates factors including the substance's physical and chemical characterization, available safety data, and whether there's a clinical need that justifies compounding it outside the standard drug approval pathway.
What the Evidence Review Found
When BPC-157 and TB-500 went through this process, the FDA's evaluation pointed to a lack of adequate safety data in humans, since the evidence base for both compounds consists overwhelmingly of animal and cell-culture studies, alongside concerns about manufacturing and quality control given how these substances were being sourced. The agency ultimately determined that both did not meet the criteria to be added to the list of substances appropriate for compounding, which functionally removed them from legitimate pharmacy channels.
What This Doesn't Mean
This determination is not the same as a definitive scientific conclusion that the compounds don't work or are unsafe at any dose. It reflects an evidentiary standard: for compounding eligibility, there needs to be a documented, adequate safety and characterization record, and that threshold hadn't been met. Peptides can remain understudied without being proven harmful, but understudied is precisely the condition that made them ineligible for a pathway meant for substances with an established record.
The Practical Effect
With BPC-157 and TB-500 excluded from compounding eligibility, licensed compounding pharmacies operating within FDA and state board rules generally can't legally prepare them for patients, which pushes availability toward the unregulated research-chemical market instead, exactly the segment with the least oversight of purity, dosing accuracy, and manufacturing quality. That's a meaningful shift for anyone considering these compounds: the regulated pathway that exists for many other peptides currently doesn't exist for these two.
Could That Change?
This determination isn't necessarily permanent. If sponsors or researchers eventually generate the kind of controlled human safety and efficacy data the FDA's review found lacking, either compound could theoretically be renominated and reevaluated for compounding eligibility, or pursue full drug approval through clinical trials. Until that happens, though, the current determination reflects the evidence as it actually stands today, not a judgment about where it might eventually land.